This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (38)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ruth B. Paulson, DDS; Martha E. Sucheston, PhD; Thomas G. Hayes, PhD; George W. Paulson, MD

Arch Neurol. 1985;42(10):980-983.

Abstract
• Valproate sodium has been implicated in the production of spina bifida in humans; this article reports an animal model. Teratogenicity of valproate sodium was studied by oral administration of single doses of 225, 340, and 560 mg/kg to pregnant CD-1 mice on days 7 through 12 of gestation. All fetuses were examined on day 17. Treated fetuses demonstrated external malformations and a decrease in weight. The incidence of malformations was greater at the higher dosage levels of 340 mg/kg and 560 mg/kg, with a predominance of exencephaly, open eyelids, and gross skeletal defects. There was a significant increase in the resorption rate of the fetuses in the treated groups. There was also a significant increase in the malformations observed per litter and per live fetus population when compared with controls.

Author Affiliations
From the Colleges of Dentistry (Dr R. Paulson) and Medicine (Drs Sucheston, Hayes, and G. Paulson), Ohio State University, Columbus.

Footnotes
Accepted for publication Dec 8,1984.

Reprint requests to Department of Neurology, Ohio State University, 1655 Upham Dr, Columbus, OH 43210 (Dr G. Paulson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Costa et al.
Pharmacol. Rev. 2004;56:103-147.
ABSTRACT | FULL TEXT